31
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Epidermal Growth Factor in Gastric Ulcer Healing by Nocloprost, a Stable Prostaglandin E2 Derivative

, , &
Pages 980-984 | Received 10 Mar 1997, Accepted 10 Jun 1997, Published online: 08 Jul 2009

References

  • Howden CW, Jones DB, Peace KE. The treatment of gastric ulcer with antisecretory drugs. Relationship of pharmacological effect to healing rates. Dig Dis Sci 1988; 33: 619–24
  • Vantrappen GJ, Jansens P, Popiela T, Kulig J, Tytgat GN, Huibregtse K, et al. Effect of (Arbaprostil) on the healing of duodenal ulcer. Gastroenterology 1982; 83: 357
  • Hawkey CJ. Prostaglandins and mucosal protection: laboratory evidence versus clinical performance. Advances in drug therapy of gastrointestinal ulcerations, A Gardner, BJR Whittle. Wiley and Sons, Chichester 1989; 89–98
  • Bianchi Porro G, Parente F. Prostaglandins as treatment for peptic ulcer: an overview of worldwide clinical experience, G Bianchi Porro, EZ Dajani. Cortina International, Amsterdam 1985; 39–51
  • Konturek SJ, Radecki T, Brzozowski T, Gryglewski R. Gastric cytoprotection by epidermal growth factor. Role of endogenous prostaglandins and DANN synthesis. Gastroenterology 1981; 81: 438–45
  • Ruppin H, Person B, Robert A, Domschke W. Gastric cytoprotection in man by prostaglandin E. Scand J Gastroenterol 1981; 16: 647–52
  • Dajani EZ, Agrawal NM. Prevention and treatment of ulcers induced ny non-steroidal anti-inflammatory drugs: an update. J Physiol Pharmacol 1995; 46: 316–9
  • Konturek SJ, Konturek JW, Kwiecien N, Obtulowicz W, Oleksy J, Hebzda Z, et al. Gastric protection by nocloprost against aspirin damage in humans. Possible role of epidermal growth factor. Scand J Gastroenterol 1991; 26: 231–6
  • Siegmund W, Zschiesche M, Franke G, Amon I. Effects of nocloprost clathrate on absorption of acetylsalicylic acid. Int J. Clin Pharmacol Ther 1994; 32: 51–7
  • Dammann HG, Dreyer M, Walter TA, Simon B, Wabnitz RW. Nocloprost, a novel prostaglandin E2 analog: significant reduction of aspirin-induced gastric lesions in man. Prog Clin Biol Res 1987; 241: 295–8
  • Calabro A, Milano S, Paladini I, Orsini B, Salvadori G, Surrenti C. Role of epidermal growth factor in peptic ulcer healing. Dig Dis Sci 1995; 40: 2497–504
  • Konturek JW, Bielanski W, Konturek SJ, Bogdal J, Oleksy J. Distribution and release of epidermal growth factor in man. Gut 1989; 30: 1194–200
  • Ohmura E, Emoto N, Tsushima T, Watanabe S, Takeuchi T, Kawamura M. Salivary immunoreactive human epidermal growth factor (IR-hEGF) in patients with peptic ulcer disease. Hepatogastroenterology 1987; 34: 160–3
  • Calabro A, Orsini B, Brocchi A, Falchini M, Fedi P, Surrenti C. Gastric juice immunoreactive epidermal growth factor levels in patients with peptic ulcer disease. Am J Gastroenterol 1990; 85: 404–7
  • Sakamoto C, Matsuda K, Nakano O, Konda Y, Matozaki T, Nishisaki H, et al. EGF stimulates both cyclooxygenase activity and cell proliferation of cultured guinea pig gastric mucous cells. J Gastroenterol 1994; 29: 73–6
  • Kelly SM, Jenner JR, Dickinson RJ, Hunter JO. Increased gastric juice epidermal growth factor after non-steroidal antiinflammatory drug ingestion. Gut 1994; 35: 611–4
  • Gilchrist W, Burkhalter E, Eaton C, Schaudies RP, Maydonovitch C, Rada F, et al. The effect of indometbacin on the secretion of human salivary epidermal growth factor. Am J Gastroenterol 1994; 89: 97–100
  • Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active gastritis. Lancet 1983; 1: 1273–5
  • Calam J. Helicobacter pylori. Chapman and Hall Medical, London 1996
  • Itoh M, Matsuo Y. Gastric ulcer treatment with intravenous human epidermal growth factor: a double blind controlled clinical study. J Gastroenterol Hepatol 1994; 9: S78–83, Suppl
  • Konturek PC, Ernst H, Konturek J, Bobrzynski A, Kwiecien N, Faller G, et al. Salivary and gastric luminal release of epidermal growth factor under basal conditions and after pentagastrin stimulation in healthy subjects and in duodenal ulcer patients before and after eradication of Helicobacter pylori. J Physiol Pharmacol 1996; 47: 187–94

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.